Also known as: T-cell growth factor (TCGF) Interleukin-2 precursor IL-2
Aldesleukin is indicated for:
Population group: both men and women, only adults (18 years old or older)
Aldesleukin is indicated for the treatment of metastatic renal cell carcinoma.
Risk factors associated with decreased response rates and median survival are:
* ECOG (Eastern Cooperative Oncology Group) 0 = normal activity, 1 = symptoms but ambulatory; 2 = in bed less than 50% of time; 3 = in bed more than 50% of time.
Response rates and median survival decrease with the number of risk factors present. Patients positive for all three risk factors should not be treated with aldesleukin.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Aldesleukin is contraindicated in the following cases: